Clinical Trials List
2017-03-01 - 2026-12-31
Phase III
Recruiting6
ICD-10C50.011
Malignant neoplasm of nipple and areola, right female breast
ICD-10C50.012
Malignant neoplasm of nipple and areola, left female breast
ICD-10C50.019
Malignant neoplasm of nipple and areola, unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.0
Malignant neoplasm of female breast, nipple and areola
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 金光亮 Division of General Surgery
- 邱仁輝 Division of General Surgery
- Yi-Fang Tsai Division of General Surgery
- 林燕淑 Division of General Surgery
- Chun-Yu Liu Division of Hematology & Oncology
- Ta-Chung Chao Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yung-Chang Lin Division of Hematology & Oncology
- Chan-Keng Yang Division of Hematology & Oncology
- 周旭桓 Division of General Surgery
- Chi-Chang Yu Division of General Surgery
- Wen-Chi Shen Division of Hematology & Oncology
- Mengting Peng Division of Hematology & Oncology
- 沈士哲 Division of General Surgery
- Wen-Ling Kuo Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 褚乃銘 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Zhu-Jun Loh Division of General Surgery
- Wei-Pang Chung Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 林季宏 Division of Hematology & Oncology
- 楊雅雯 Division of General Surgery
- MING-YANG WANG Division of General Surgery
- 羅喬 Division of General Surgery
- 郭文宏 Division of General Surgery
- YEN-SHEN LU Division of Hematology & Oncology
- 林柏翰 Division of General Internal Medicine
- 蔡立威 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
約50 participants
-
Global
約855 participants
